Literature DB >> 10455323

Spontaneously hypertensive rats cholinergic hyper-responsiveness: central and peripheral pharmacological mechanisms.

E Lazartigues1, C Brefel-Courbon, M A Tran, J L Montastruc, O Rascol.   

Abstract

1. The mechanisms and the subtypes of muscarinic receptors implicated in the cardiovascular effects of physostigmine were investigated in conscious normotensive and spontaneously hypertensive rats. 2. Intravenous (i.v.) physostigmine (50 microg kg-1) induced in both strains a long pressor response, accompanied by a bradycardia. This pressor response was larger in spontaneously hypertensive (+41+/-6 mmHg) than in Wistar-Kyoto (+25+/-2 mmHg) rats (P<0.05). 3. Pretreatment with atropine sulphate (0.4 mg kg-1 i.v.), completely abolished the physostigmine-induced pressor response in both normotensive and hypertensive rats. In both strains, the physostigmine pressor response was significantly reduced by the systemic administration of either an alpha1-adrenoceptor antagonist (prazosin, 1 mg kg-1) or a V1A-vasopressin receptor antagonist (AVPX, 20 microg kg-1). This physostigmine pressor effect was completely abolished in both strains when both antagonists were administered concomitantly. 4. In WKY rats, the pressor response to physostigmine (50 microg kg-1 i.v.) was inhibited in a dose-dependent manner by i. c.v. administration of atropine (ID50=3.70 nmoles), the M1 receptor antagonist pirenzepine (ID50=10.71 nmoles), the M2 receptor antagonist methoctramine (ID50=4.31 nmoles), the M3 receptor antagonist p-F-HHSiD (ID50=60.52 nmoles) and the M4 receptor antagonist tropicamide (ID50=214.20 nmoles). In the hypertensive strain, the ID50 were found to be significantly higher for atropine (7.34 nmoles), pirenzepine (21.60 nmoles) and p-F-HHSiD (139.50 nmoles) (P<0.05). 5. The present results indicate that physostigmine acts in normotensive and spontaneously hypertensive rats, through stimulation of both central M2 and M1 cholinoceptors to induce a rise in blood pressure mediated by an increase in plasma vasopressin and sympathetic outflow. Moreover, our results suggest that some modifications of the M1 receptor subtypes in terms of expression or affinity could be responsible for the hyper-responsiveness of the hypertensive strain to cholinomimetic agents.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10455323      PMCID: PMC1566139          DOI: 10.1038/sj.bjp.0702678

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  44 in total

1.  Pressor response to posterior hypothalamic administration of carbachol is mediated by muscarinic M3 receptor.

Authors:  J R Martin
Journal:  Eur J Pharmacol       Date:  1992-04-29       Impact factor: 4.432

2.  Cholinergic systems in mammalian brain identified with antibodies against choline acetyltransferase.

Authors:  B H Wainer; A I Levey; E J Mufson; M M Mesulam
Journal:  Neurochem Int       Date:  1984       Impact factor: 3.921

3.  Cardiovascular regulation by cholinergic mechanisms in rostral ventrolateral medulla of spontaneously hypertensive rats.

Authors:  S B Lee; S Y Kim; K W Sung
Journal:  Eur J Pharmacol       Date:  1991-11-26       Impact factor: 4.432

Review 4.  The role of central cholinergic neurons in the regulation of blood pressure and in experimental hypertension.

Authors:  J J Buccafusco
Journal:  Pharmacol Rev       Date:  1996-06       Impact factor: 25.468

5.  M3 muscarinic receptors mediate cholinergic excitation of the spontaneous activity of subthalamic neurons in the rat.

Authors:  G Flores; S Hernandez; M G Rosales; A Sierra; D Martines-Fong; J Flores-Hernandez; J Aceves
Journal:  Neurosci Lett       Date:  1996-01-26       Impact factor: 3.046

6.  The pressor response to spinal cholinergic stimulation in spontaneously hypertensive rats.

Authors:  J J Buccafusco; V Magri
Journal:  Brain Res Bull       Date:  1990-07       Impact factor: 4.077

7.  Modulation of genetic hypertension by short-term AVP V1A or V2 receptor antagonism in young SHR.

Authors:  M Naitoh; L M Burrell; J Risvanis; K L Aldred; M D Rockell; C I Johnston; P A Phillips
Journal:  Am J Physiol       Date:  1997-02

8.  Cardiovascular effects of central injection of acetylcholine in anaesthetized dogs: a role for vasopressin release.

Authors:  O Rascol; J L Montastruc; G Gauquelin; M A Tran; G Geelen; C Gharib; P Montastruc
Journal:  Br J Pharmacol       Date:  1990-07       Impact factor: 8.739

9.  Muscarinic cholinoceptors and choline acetyltransferase activity in the hypothalamus of spontaneously hypertensive rats.

Authors:  S Yamada; T Ishima; M Hayashi; T Tomita; E Hayashi
Journal:  Life Sci       Date:  1984-05-28       Impact factor: 5.037

10.  M2 muscarinic receptors mediate pressor responses to cholinergic agonists in the ventrolateral medullary pressor area.

Authors:  K Sundaram; A J Krieger; H Sapru
Journal:  Brain Res       Date:  1988-05-24       Impact factor: 3.252

View more
  4 in total

1.  The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptors.

Authors:  Adrienne J Betz; Peter J McLaughlin; Melissa Burgos; Suzanne M Weber; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2007-06-27       Impact factor: 4.530

2.  Autonomic and cholinergic mechanisms mediating cardiovascular and temperature effects of donepezil in conscious mice.

Authors:  Aaron J Polichnowski; Geoffrey A Williamson; Tesha E Blair; Donald B Hoover
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2021-04-14       Impact factor: 3.210

3.  Pharmaceutical Assessment Suggests Locomotion Hyperactivity in Zebrafish Triggered by Arecoline Might Be Associated with Multiple Muscarinic Acetylcholine Receptors Activation.

Authors:  Petrus Siregar; Gilbert Audira; Ling-Yi Feng; Jia-Hau Lee; Fiorency Santoso; Wen-Hao Yu; Yu-Heng Lai; Jih-Heng Li; Ying-Ting Lin; Jung-Ren Chen; Chung-Der Hsiao
Journal:  Toxins (Basel)       Date:  2021-04-03       Impact factor: 4.546

4.  The contributions of muscarinic receptors and changes in plasma aldosterone levels to the anti-hypertensive effect of Tulbaghia violacea.

Authors:  Ismaila Raji; Pierre Mugabo; Kenechukwu Obikeze
Journal:  BMC Complement Altern Med       Date:  2013-01-11       Impact factor: 3.659

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.